- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05500040
Changes in Faecal Calprotectin Levels and Participation-related Scores Following Three Weeks of Inpatient Rehabilitation
Veränderungen Des Faecalen Calprotectinwertes Und Teilhabebezogener Scores in Folge Einer dreiwöchigen Phase II Rehabilitation [Changes in Faecal Calprotectin Levels and Participation-related Scores Following Three Weeks of Inpatient Rehabilitation]
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Benedikt Steininger, MSc
- Phone Number: +435030326715
- Email: benedikt.steininger@pv.at
Study Locations
-
-
Styria
-
Vienna, Styria, Austria, 8990
- Rehabilitationszentrum Bad Aussee
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of Crohn's Disease or Ulcerative Colitis
- Participation in an inpatient phase II rehabilitation
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with IBD - Crohn's Disease
|
The rehabilitation measure is based on the biopsychosocial ICF model of the WHO.
A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation.
Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
|
Patients with IBD - Ulcerative Colitis
|
The rehabilitation measure is based on the biopsychosocial ICF model of the WHO.
A multidisciplinary team of therapists looks after the patients during their stay in rehabilitation.
Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to their needs.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Faecal Calprotectin
Time Frame: 3 weeks of inpatient rehabilitation
|
Faecal calprotectin is a biochemical measurement of the protein calprotectin in the stool.
Elevated faecal calprotectin indicates the migration of neutrophils to the intestinal mucosa, which occurs during intestinal inflammation, including inflammation caused by inflammatory bowel disease.
|
3 weeks of inpatient rehabilitation
|
Ced Disk
Time Frame: 3 weeks of inpatient rehabilitation
|
The Ced Disk measures IBD-related impairments in different dimensions i.e., abdominal pain, bowel control, interpersonal interactions, education and work, sleep, energy, emotions, body image, sexuality, joint pain (Min.
= 0, Max.
= 10).
Lower values indicate less impairments in the respective dimensions.
|
3 weeks of inpatient rehabilitation
|
European Quality of Life 5 Dimensions 5 Level (EQ-5D-5L)
Time Frame: 3 weeks of inpatient rehabilitation
|
The EQ-5D-5L is a general instrument for measuring patient-reported outcomes (PROs), which can be used to assess the quality of life of patients on different dimensions (mobility, self-care, usual activities, pain/discomfort) on a 5-level scale (Min. = 0, Max. = 5). Lower values indicate less impairments in the respective dimensions. Moreover, the EQ-5D-5L assesses the patient's self-rated health on a 100 point visual analog scale (Min. = 0, Max. = 100). Lower values indicate less positive ratings of health. |
3 weeks of inpatient rehabilitation
|
Patient Health Questionnaire-4 (PHQ-4)
Time Frame: 3 weeks of inpatient rehabilitation
|
The Patient Health Questionnaire-4 (PHQ-4) operationalizes core criteria for anxiety and depression on a 4 point likert scale (Min.
= 0, Max = 4).
Lower values indicate less impairments.
|
3 weeks of inpatient rehabilitation
|
Work ability index (WAI)
Time Frame: 3 weeks of inpatient rehabilitation
|
The Work Ability Index (WAI) is an instrument for assessing work ability.
(Min.
= 7, Max = 49).
Lower values indicate less subjective work ability.
|
3 weeks of inpatient rehabilitation
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: David Felder, Mag., Pensionsversicherungsanstalt
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0008-CED
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Multimodal Rehabilitation
-
Karolinska InstitutetThe Swedish Research Council; Karolinska Institutet: Doctoral School in Health...UnknownChronic Pain | Widespread Chronic PainSweden
-
University of ValenciaCompletedEnhanced Recovery | Fast Track
-
Uppsala UniversityCompletedChronic Pain | Complex Regional Pain SyndromesSweden
-
National Institute of Geriatrics, Rheumatology...CompletedComplex Regional Pain SyndromesPoland
-
Zhongnan HospitalRecruitingConcurrent Chemoradiotherapy;Nutrition;Multimodal RehabilitationChina
-
PensionsversicherungsanstaltCompleted
-
Damla Korkmaz DayicanDokuz Eylul University; Biruni UniversityRecruitingUrinary Incontinence | Nocturnal Enuresis | Pelvic Floor Disorders | Children, Only | Pediatric Disorder | Daytime WettingTurkey
-
Consorci Sanitari de TerrassaCompleted
-
Dalarna UniversityThe Swedish Research Council; ForteCompleted
-
Universidade Federal de Santa MariaCompletedChronic Obstructive Pulmonary DiseaseBrazil